Abstract
Objective To analyze the role of contrast-enhanced ultrasound (CEUS) parameters combined with serum tumor marker CA153 in the prediction of Breast Cancer (BC) molecular typing.
Methods From January 2020 to January 2023, 120 BC patients diagnosed in our hospital were studied. According to the pathological results, the patients were divided into Luminal and non-Luminal BC groups. Both groups underwent contrast-enhanced ultrasoun. The time-intensity curve (TIC) is obtained, and the relevant characteristic parameters are obtained, including peak intensity (PI), peak time (TTP), area under the curve (AUC), and mean transit time (MTT). Serum tumor marker CA153 was detected in both groups. Combined with CEUS characteristic parameters and serum CA153 of two groups of BC patients, a multiple Logistic regression model was constructed, and a nomogram prediction model was constructed based on the model. Calibration curve and receiver operating characteristic (ROC) curve were used to analyze the value of this model in the prediction of BC molecular classification.
Results There were no significant differences between Luminal BC patients and non-Luminal BC patients in clinical parameters and qualitative parameters of contrast-enhanced ultrasound, while there were statistical differences between quantitative parameters PI, AUC and serum tumor marker CA153. The AUC of the combined diagnosis of three parameters (PI, AUC and CA153) was significantly higher than that of the single index diagnosis group. The ROC curve AUC of BC molecular typing was predicted to be 0.94 based on the three-parameter nomogram, and the fitting of the actual curve and the ideal curve in the calibration curve was close.
Conclusions The nomogram model based on breast contrast-enhanced ultrasound (CEUS) parameters combined with serum CA153 can effectively predict the molecular classification of BC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of Shandong Provincial Cancer Prevention and Treatment Research Institute (SDTHEC2023003011).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
NO
